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ABSTRACT
Objective: To investigate the possible association
between total daily iron intake during pregnancy,
haemoglobin in early pregnancy and the risk of
gestational diabetes mellitus (GDM) in women at
increased risk of GDM.
Design: A prospective cohort study (based on a
cluster-randomised controlled trial, where the
intervention and the usual care groups were
combined).
Setting: Primary healthcare maternity
clinics in 14 municipalities in south-western
Finland.
Participants: 399 Pregnant women who were at
increased risk of GDM participated in a GDM
prevention trial and were followed throughout
pregnancy.
Main outcome measurements: The main
outcome was GDM diagnosed with oral glucose
tolerance test at 26–28 weeks’ gestation or based
on a diagnosis recorded in the Finnish Medical
Birth registry. Data on iron intake was collected
using a 181-item food frequency questionnaire and
separate questions for supplement use at 26–
28 weeks’ gestation.
Results: GDM was diagnosed in 72 women
(18.1%) in the study population. The OR for total
iron intake as a continuous variable was 1.006
(95% CI 1.000 to 1.011; p=0.038) after adjustment
for body mass index, age, diabetes in first-degree
or second-degree relatives, GDM or macrosomia in
earlier pregnancy, total energy intake, dietary fibre,
saturated fatty acids and total gestational weight
gain. Women in the highest fifth of total daily iron
intake had an adjusted OR of 1.66 (95% CI 0.84 to
3.30; p=0.15) for GDM. After excluding participants
with low haemoglobin levels (≤120 g/l) already in
early pregnancy the adjusted OR was 2.35 (95% CI
1.13 to 4.92; p=0.023).
Conclusions: Our results suggest that high iron
intake during pregnancy increases the risk of GDM
especially in women who are not anaemic in early
pregnancy and who are at increased risk of GDM.
These findings suggest that routine iron
supplementation should be reconsidered in this
risk group of women.
ARTICLE SUMMARY
Article focus
▪ The objective of this study was to investigate the
possible association between total daily iron intake
from both food and supplements during pregnancy,
haemoglobin levels in early pregnancy and the risk
of gestational diabetes in women at increased risk
of gestational diabetes mellitus (GDM).
Key messages
▪ Our results suggest that high iron intake during
pregnancy increases the risk of GDM especially
in women who are not anaemic in the beginning
of the pregnancy and who are at increased risk
of GDM.
▪ Our findings suggest that routine iron supplemen-
tation should be reconsidered in this risk group of
women.
Strengths and limitations of this study
▪ Unlike most of the previous studies we had
detailed information of iron intake from both
food and supplements.
▪ We had information of baseline OGTT and could
therefore excludewomen with undiagnosed prepreg-
nancy diabetes. Additionally Finnish Medical Birth
Registry could be utilised to cover those GDM cases
that were undiagnosed in the 26–28 weeks’OGTT.
▪ We also had information of haemoglobin mea-
surements of the study population during preg-
nancy although measured by nurses.
▪ All of our data was collected prospectively.
▪ The participation rate in the original trial was high
(88% in both the intervention and the usual care
groups) improving the generalisability of the results
to other women with risk factors for GDM.
▪ Iron intake was assessed at a certain point in
time, thus it does not cover the intake during the
whole pregnancy.
▪ We could not assess iron absorption.
▪ The haemoglobin levels were screened at the
maternity clinics using finger-stick samples,
which may not be an optimal measurement tool.
▪ Haemoglobin measurements were missing for 28
women at 8–12 weeks’ gestation and we used the
measurement at 16–18 weeks’ gestation for those
women.
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INTRODUCTION
Gestational diabetes mellitus (GDM) is a disturbance in
glucose metabolism, which is diagnosed during preg-
nancy and affects 1–14% of pregnancies in different
populations.1 The incidence of gestational diabetes has
been increasing the last 20 years.2 Risk factors for GDM
include higher maternal body mass index (BMI), higher
age and family history of diabetes.3 Approximately half
of the GDM cases can be explained by overweight.4
GDM causes short-term and long-term risks to both the
mother and the child. The most common result of GDM
is newborn macrosomia, which increases several adverse
outcomes during delivery such as shoulder dystocia,
perineal lacerations, blood loss and increased caesarean
birth.5 GDM also increases the risk of glucose metabol-
ism disorders and type 2 diabetes in later life of the
mother and the newborn.6 7
High iron load and disorders of iron metabolism have
been associated with an increased risk of disturbances in
glucose metabolism.8–10 In hereditary hemochromatosis
iron accumulation in the body leads to diabetes in 30–
60% of patients.11 Also in animal models iron has been
shown to induce diabetes.12 Iron binding medication is
effective in preventing diabetes in iron overload condi-
tions.13 Frequent blood donation has been shown to
result in improvement in glucose metabolism even in
healthy people.14 Higher iron stores have been found in
gestational diabetes patients measured most commonly
by serum ferritin.15–17 High haemoglobin level in early
pregnancy has been reported to be an independent risk
factor for GDM18 and lower haemoglobin levels and
anaemia during pregnancy have been shown to result in
lower risk of GDM.19 A large proportion of women, up
to 78% in Finland,20 use supplemental iron during preg-
nancy even with good haemoglobin levels and thus it is
an important matter to investigate the possible adverse
effects of iron. High iron intake could be especially risky
for women with already good iron stores.
Studies of total iron intake and the risk of GDM are
scarce: only Bowers et al21 have investigated pre-
pregnancy total iron intake in relation to the risk of
GDM. Other studies have investigated iron intake either
from food or supplements only and have thus failed to
report the effect of total iron intake.22 23 Only one
placebo controlled clinical trial has been conducted on
supplemental iron and the risk of GDM.24 To our knowl-
edge there are no published studies of total iron intake
during pregnancy, haemoglobin and the risk of GDM.
The objective of this study was to investigate the possible
association between total daily iron intake from both
food and supplements during pregnancy, haemoglobin
levels in early pregnancy and the risk of gestational dia-
betes in women at increased risk of GDM.
MATERIAL AND METHDOS
The data of this study were originally collected as a part
of a larger gestational diabetes prevention trial, which is
described in more detail elsewhere.25 The effects of the
intervention on GDM and newborns birth weight have
been reported elsewhere.26 This cluster-randomised trial
was carried out in 14 municipalities in Pirkanmaa region
in south-western Finland in 2007–2009. The municipal-
ities were randomised in pairs into intervention and
usual care municipalities.
The inclusion criteria for the trial were to have at least
one of the following risk factors: BMI ≥25 kg/m2; age
≥40 years; GDM, glucose intolerance or newborn’s
macrosomia (≥4500 g) in any earlier pregnancy or type 1
or 2 diabetes in ﬁrst-degree or second-degree relatives.
Women were excluded from the trial if they had an
abnormal measurement in the baseline (8–12 weeks’ ges-
tation) glucose tolerance test (fasting blood glucose
≥5.3 mmol/l, >10.0 mmol/l at 1 h or >8.6 mmol/l at
2 h); pre-pregnancy diabetes (type 1 or 2); age <18 years;
no Finnish language skills; multiple pregnancy; restric-
tions from physical activity; substance abuse or psychiatric
illness. The trial was approved by the ethical committee
of Pirkanmaa Hospital District and written informed
consent was provided by the participants.
A total of 2271 women were screened for the study
and of them 726 were preliminary eligible to participate
in the study.26 Of these women 640 (88.2%) gave an
informed consent to participate in the trial. At the base-
line (8–12 weeks’ gestation) oral glucose tolerance test
174 women had an abnormal result and were thus
excluded. Furthermore 38 women had a miscarriage
and 29 were lost to follow-up. Finally, 399 participants
were included in the analyses (219 in the intervention
group and 180 in the usual care group).
The intervention group participated in individual
counselling on weight gain, physical activity and diet on
ﬁve antenatal visits in primary healthcare maternity
clinics. The objectives of the counselling were to guide
the participants in monitoring their weight gain, increas-
ing or maintaining their leisure time physical activity
and achieving a healthy diet fulﬁlling the national
recommendations. The effects of intensiﬁed dietary
counselling on food habits and the intake of energy,
energy-yielding nutrients, ﬁbre, selected fatty acids and
cholesterol have been reported elsewhere.27 The coun-
selling was not aiming to inﬂuence in iron intake. In
this study the intervention and usual care groups were
combined and these groups had no differences in the
incidence of GDM or in iron intake.
Background information of the participants was gath-
ered with a baseline questionnaire at the ﬁrst prenatal
visit (8–12 weeks’ gestation). Information of pre-
pregnancy BMI (weight self-reported and height mea-
sured at 8–12 weeks’ visit) and haemoglobin were
abstracted from maternity cards. In this study we used
information of haemoglobin measurements from early
pregnancy (weeks 8–12, or 16–18 for those with missing
values for 8–12 weeks) to determine the status of body
iron stores in the beginning of pregnancy and before
the physiological decrease in haemoglobin levels. The
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participants were considered to have good haemoglobin
levels if they had a haemoglobin measurement of over
120 g/l according to the lower limit for normal haemo-
globin in non-pregnant women.28 The limit for normal
haemoglobin in pregnant women (110 g/l) was not
used because of low frequency of cases with haemoglo-
bin level under 110 g/l in early pregnancy (n=7). All
women underwent a 75 g oral glucose tolerance test at
26–28 weeks’ gestation. The criterion for gestational dia-
betes diagnosis was to have at least one abnormal value:
fasting glucose after an overnight fast ≥5.3 mmol/l,
blood glucose >10.0 mmol/l 1 h after or >8.6 mmol/l
2 h after consuming 75 g of glucose. To cover all possible
cases information of gestational diabetes was abstracted
from the Finnish Medical Birth Register.
Information on diet and supplement use was obtained
by a validated 181-item food frequency questionnaire29
although the validity of the supplement data was not
assessed in the study by Erkkola et al. The participants
completed the questionnaire at 8–12 weeks’ gestation
and again at 26–28 and 36–37 weeks’ gestation. In the
8–12 weeks’ questionnaire the participants were asked
about their dietary habits during 1 month before begin-
ning of the pregnancy and in 26–28 and 36–37 weeks’
questionnaires the participants were asked about their
dietary habits during the previous month. The com-
pleted questionnaires were checked by a nutritionist and
those with more than 10 missing values in the frequency
data were completed after consulting the participant on
the phone. In the food frequency questionnaire the
dietary habits were assessed by detailed questions of fre-
quency of use (per day, week, month or not at all) and
the portion sizes of speciﬁc food items. The participants
were also asked to report their supplement use: brand
name of the supplement, dosage and frequency of use
(per day, week or month). The gathered data were then
entered into a food database using a software program
of the National Institute for Health and Welfare,
Helsinki, Finland, and coded to daily food record
form. Nutrient intakes were calculated by using the
10th release (updated in 2009) of the Finnish Food
Composition Database Fineli (http://www.ﬁneli.ﬁ) and
in-house software of the National Institute for Health
and Welfare. In this study information of dietary habits
and supplement use at 26–28 weeks of gestation was
used to get the best estimation of iron intake and the
intake of energy, macronutrients and dietary ﬁbre
during pregnancy and before the onset of GDM.
Statistical methods
The study population was categorised into ﬁve equal
groups according to their total daily iron intake. To
better see the differences between women in the highest
ﬁfth of total iron intake and the other women, we com-
bined the three groups in the middle (20%, 60% and
20%). The groups were tested for possible differences
in risk factors, dietary intake and other background
characteristics using χ2 test, Kruskal-Wallis test or
One-way analysis of variance. The incidence of GDM was
then investigated between the iron intake groups and
the differences were tested statistically using χ2 or Fisher
exact tests. Haemoglobin was considered as a potential
effect modiﬁer. Women were divided into two groups
according to their haemoglobin level in early pregnancy:
>120 or ≤120 g/l.
Logistic regression was used to assess the OR for gesta-
tional diabetes. The dependent variable in the regres-
sion model was GDM (yes/no). In the ﬁrst model iron
intake was assessed as a continuous variable. In the
second model the highest ﬁfth of total iron intake
(intake ≥110 mg) was compared to the rest of the study
population (iron intake under 110 mg). The models
were adjusted for BMI, age, intake of energy, saturated
fatty acids and dietary ﬁbre and total gestational weight
gain (all as continuous) as well as diabetes in ﬁrst-degree
or second-degree relatives and GDM or macrosomia in
earlier pregnancy (both as categorical). Both models
were executed separately for all women and for women
with haemoglobin levels over 120 g/l in early pregnancy
(8–12 or 16–18 weeks’ gestation).
We also added interaction terms for iron intake and
haemoglobin and for iron intake and BMI to the model
but they were not statistically signiﬁcant and therefore
are not presented here. In sensitivity analyses, we exam-
ined the association between the total iron intake and
the risk of GDM using alternative cut-off points for cate-
gorising participants based on their iron intake (15%,
70% and 15%; 25%, 50% and 25% and 30%, 40% and
30%) and the same statistical tests as described above.
All analyses were performed with SPSS statistics (V.19).
RESULTS
On the basis of the questionnaire completed at 26–28
weeks’ gestation, the mean daily iron intake from food
was 14.4 mg (SD 4.3; median 13.9 mg) among the study
population. In the study group 65.7% of women used
supplemental iron and the median of supplemental
intake was 27 mg. The most used dosages for iron sup-
plementation were 10, 20 and 100 mg of elemental iron
(Fe2+). The median for total iron intake was 27.1 mg
(IQR 15.5–89.3 mg; ﬁgure 1). Iron intake from food was
similar in non-users and users of supplemental iron:
users of supplemental iron had a mean daily intake of
14.5 mg (SD 4.5) and nonusers 14.3 mg (SD 3.9). The
mean haemoglobin level of the study population in the
beginning of pregnancy was 134 g/l (SD 11; minimum
107 and maximum 169 g/l).
The oral glucose tolerance test at 26–28 weeks’ gesta-
tion was abnormal in 14% of the study population
(n=56, missing value for three women). Furthermore
16 women received a gestational diabetes diagnosis
during their pregnancy. Figure 2 shows the incidence of
GDM in ﬁfths of total iron intake. There was a tendency
for a higher incidence of GDM in the highest ﬁfth of
total iron intake.
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Between the iron intake groups (20%, 60% and 20%)
there were no signiﬁcant differences in terms of propor-
tion of primigravida, age, diabetes in ﬁrst-degree or
second-degree relatives or GDM or macrosomia in
earlier pregnancy (table 1). Women in the highest iron
intake group had a slightly lower mean BMI as com-
pared with other women (p=0.05). Haemoglobin levels
in early pregnancy differed between the groups as
excepted (p<0.001). With regard to differences in
dietary intake, women in the lowest iron intake group
had lower total energy and dietary ﬁbre intakes than the
other women whereas women in the highest iron intake
group had higher intake of saturated fatty acids than the
other women. Total gestational weight gain did not
differ between the iron intake groups. Table 2 shows the
incidence of GDM in the three iron intake groups. The
incidence was higher in the highest iron intake group
(20.8%) compared to the other two groups (16.7% in
both) but the difference was not statistically signiﬁcant
(p0.70). When including women with haemoglobin
levels >120 g/l in early pregnancy (n=321, mean Hb
135, SD 9), the difference between the groups was even
larger but still not statistically signiﬁcant (p=0.11).
The logistic regression model shows that after adjust-
ment for potential risk factors and background
characteristics total iron intake was signiﬁcantly and
positively associated with gestational diabetes mellitus
(table 3). When iron intake was used as a continuous
variable the OR was 1.006 (p=0.038) for all women and
1.009 (p=0.006) for those with haemoglobin levels over
120 g/l. In the second model, the OR for GDM was 1.66
(95% CI 0.84 to 3.30, p=0.15) for the highest ﬁfth of
iron intake among all women. After excluding women
with low haemoglobin levels (≤120 g/l) in early preg-
nancy the OR was 2.35 (95% CI 1.13 to 4.92, p=0.023).
In sensitivity analyses the ORs were higher when 15%
of women with the highest iron intake were compared
to the rest 85% of women. The ORs were lower when
25% or 30% of women with highest intake were com-
pared to the rest 75% and 70% of women, respectively
(results not shown).
DISCUSSION
In this study we investigated the possible association
between total daily iron intake during pregnancy,
haemoglobin in early pregnancy and the risk of gesta-
tional diabetes. To our knowledge there are no similar
studies published previously. We discovered that there
was a tendency for a higher incidence of GDM in the
highest ﬁfth of total iron intake. High iron intake
increased the risk of GDM especially for those women
who had good haemoglobin levels in early pregnancy:
we discovered a twofold OR for GDM for women in the
highest ﬁfth of iron intake with a haemoglobin level of
over 120 g/l in early pregnancy.
Our study has several strengths. First unlike most of
the previous studies we had detailed information of iron
intake from both food and supplements. Second, we
had information on baseline oral glucose tolerance test
(OGTT) and could therefore exclude women with
undiagnosed pre-pregnancy diabetes. Additionally,
Finnish Medical Birth Registry could be utilised to cover
those GDM cases that were undiagnosed in the 26–
28 weeks’ OGTT. We also had information of haemoglo-
bin measurements of the study population during preg-
nancy although measured by nurses. All of our data was
collected prospectively. The participation rate in the ori-
ginal trial was high (88% in both the intervention and
the usual care groups) improving the generalisability of
the results to other women with risk factors for GDM.
A limitation of this kind of study is that estimating iron
intake during pregnancy can be challenging because
dietary habits and use of supplements can vary a lot
during pregnancy due to nausea and other changes in
well-being. Iron intake was assessed at a certain point in
time (at 26–28 weeks’ gestation covering the previous
month), thus it does not cover the intake during the
whole pregnancy. In our study, we decided to use infor-
mation of iron intake in mid-pregnancy to get the best
estimation on iron intake during pregnancy and before
the onset of GDM. We did not use information of iron
intake abstracted in the beginning of pregnancy because
Figure 1 Total iron intake in mid pregnancy (26–28 weeks’
gestation).
Figure 2 Incidence of GDM (%) in fifths of total iron intake.
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it covered only dietary habits and supplement use
during 1 month before the pregnancy when use of sup-
plemental iron is rare. However, our information on
iron intake covers only 1 month in the mid-pregnancy.
Additionally we could not assess iron absorption, for
example with blood measurements, which also can
vary a lot depending on body iron status and the con-
tents of meals.
There are also limitations concerning the haemoglo-
bin measurements used in our study. In the maternity
clinics haemoglobin levels are usually screened with a
capillary haemoglobin measurement using ﬁnger-stick
samples. This method has been demonstrated to be
reliable in determining haemoglobin values but it is
however susceptible to handling errors30 and therefore
there can be variation in the test results. Additionally, we
had a lot of missing values in haemoglobin measure-
ments and thus we decided to use the haemoglobin
measurement at 16–18 weeks’ gestation for those with
missing values at weeks 8–12 (n=28). Although measure-
ments at weeks 16–18 do not present the haemoglobin
levels at early pregnancy our objective was to analyse sep-
arately women who were not anaemic and thus includ-
ing women who had a haemoglobin level of over 120 g/l
still at weeks 16–18 would help us not to underestimate
the proportion of women who were not anaemic in the
beginning of the pregnancy. However, for these reasons
our results with respect to haemoglobin measurements
should be considered with caution and further studies
with reliable and comprehensive haemoglobin measure-
ments are warranted to conﬁrm our results.
In a somewhat similar study Bo et al22 discovered that
women who used supplemental iron during mid-
pregnancy had a twofold to threefold risk of GDM. They
however had no information of dietary intake of iron or
haemoglobin levels or other measurements of iron
stores. Their ﬁndings are however in line with our








Total Fe intake (mg/day) 11.6 (2.0) 36.0 (25.1) 136.2 (36.5) –
Primigravida 34 (43.6) 96 (41.2) 43 (55.1) 0.099*
BMI (kg/m2) 26.7 (4.4) 26.5 (4.7) 25.2 (4.3) 0.050†
Age (years) 29.3 (5.1) 29.8 (4.4) 29.6 (5.4) 0.70†
Diabetes in first-degree or second-degree
relatives
44 (57.1) 127 (54.5) 48 (61.5) 0.55*
GDM or macrosomia in previous pregnancy 14 (18.2) 33 (14.2) 10 (12.8) 0.60*
Hb (8–12 weeks‡) (g/l) 135.4 (9.6) 134.0 (10.9) 127.0 (10.0) <0.001§
Total energy intake (MJ/day) 8.3 (1.5) 10.1 (2.6) 9.9 (2.7) <0.001†
Protein (E%)¶ 18.0 (2.3) 18.0 (2.2) 18.1 (2.2) 0.81§
Carbohydrates (E%) 48.0 (4.4) 48.6 (4.8) 47.3 (4.9) 0.071§
Saccharose (E%) 10.7 (3.4) 10.6 (3.4) 10.8 (2.6) 0.54‡
Dietary fibre (g/day) 20.7 (6.0) 26.8 (9.2) 25.8 (8.6) <0.001§
Total fat (E%) 32.9 (4.0) 32.3 (4.4) 33.4 (4.1) 0.099§
Saturated fatty acids (E%) 12.7 (2.0) 12.5 (2.7) 13.3 (2.5) 0.015‡
Monounsaturated fatty acids (E%) 12.1 (1.9) 11.9 (1.8) 12.2 (1.7) 0.57§
Polyunsaturated fatty acids (E%) 5.2 (1.0) 5.0 (0.9) 5.0 (0.9) 0.85§
Total gestational weight gain (kg) 14.1 (5.5) 13.9 (5.3) 14.5 (5.4) 0.81§
*χ2 test.
†Kruskal-Wallis test.
‡16–18 for those with missing values at 8–12 weeks (n=28), missing: Hb n=5, 20 and 6, respectively.
§One-way ANOVA.
¶Percentage of total energy intake. Data on dietary intake was collected by the food frequency questionnaire completed at 26–28 weeks’
gestation.
ANOVA, analysis of variance; BMI, body mass index; GDM, gestational diabetes mellitus; Hb, haemoglobin.








(20%) <14.2 mg/day 78 13 (16.7) 0.70*
(60%) 14.2–109.9 mg/day 233 39 (16.7)
(20%) 110.0+ mg/day 78 16 (20.8)
Hb (8–12 weeks†) >120 g/l
(20%) <14.2 mg/day 69 13 (18.8) 0.11*
(60%) 14.2–109.9 mg/day 194 30 (15.5)
(20%) 110.0+ mg/day 58 16 (27.6)
Hb (8–12 weeks†) ≤120 g/l
(20%) <14.2 mg/day 3 0 0.45‡
(60%) 14.2–109.9 mg/day 21 3 (14.3)
(20%) 110.0+ mg/day 12 0
*χ2 test.
†16–18 for those with missing values at 8–12 weeks (n=28).
‡Fisher’s exact test.
GDM, gestational diabetes mellitus; Hb, haemoglobin.
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results which suggest that dietary intake could play a
relatively small part in the association whereas high sup-
plemental iron intake could be responsible for most
of the increase in GDM risk. Somewhat different
results have been reported recently by Bowers et al21 and
Qiu et al.23 Bowers et al21 investigated dietary and supple-
mental iron intake during 1 year before pregnancy utilis-
ing the material from the Nurses Health study. They
observed no signiﬁcant effect of total, non-heme or
supplemental iron intake on the risk of GDM. It can be
argued though that usually iron supplementation
outside of pregnancy is rare and concerns mainly those
who are anaemic. However, they did ﬁnd a signiﬁcant
and positive association between haeme iron intake and
GDM. Similarly Qiu et al23 demonstrated an association
between haeme iron intake during the time before con-
ception and in early pregnancy and the risk of GDM. To
our knowledge only one placebo-controlled clinical trial
Table 3 Incidence of GDM, unadjusted and adjusted ORs (95% CI) for iron intake at 26–28 weeks’ gestation as a
continuous and a categorical variable separately for all women and for women with haemoglobin >120 g/l
Unadjusted OR (95% CI) p Value Adjusted OR (95% CI)* pValue
Fe intake as a continuous variable
All women
Total Fe intake (mg/day) 1.004 (0.999 to 1.008) 0.16 1.006 (1.000 to 1.011) 0.038
BMI 1.09 (1.02 to 1.16) 0.006
Age 1.01 (0.95 to 1.07) 0.78
Diabetes in first-degree or second-degree relatives 0.87 (0.49 to 1.55) 0.63
GDM or macrosomia in a previous pregnancy 1.77 (0.86 to 3.64) 0.12
Total energy intake (MJ/day) 0.89 (0.74 to 1.06) 0.19
Dietary fibre (g/day) 1.02 (0.97 to 1.08) 0.43
Saturated fatty acids (E%)† 0.96 (0.84 to 1.09) 0.48
Total gestational weight gain 0.94 (0.89 to 1.00) 0.039
Women with Hb (8–12 weeks’ gestation‡) >120 g/l
Total Fe intake (mg/day) 1.007 (1.001 to 1.012) 0.013 1.009 (1.003 to 1.015) 0.006
BMI 1.07 (1.00 to 1.15) 0.042
Age 1.01 (0.94 to 1.08) 0.78
Diabetes in first-degree or second-degree relatives 0.73 (0.39 to 1.36) 0.32
GDM or macrosomia in a previous pregnancy 1.78 (0.80 to 3.95) 0.16
Total energy intake (MJ/day) 0.83 (0.68 to 1.01) 0.066
Dietary fibre (g/day) 1.04 (0.99 to 1.10) 0.14
Saturated fatty acids (E%)† 0.98 (0.84 to 1.13) 0.75
Total gestational weight gain 0.93 (0.88 to 0.99) 0.028
Fe intake as a categorical variable
All women
Total Fe intake (the highest 20% vs the lowest 80%) 1.31 (0.70 to 2.44) 0.40 1.66 (0.84 to 3.30) 0.15
BMI 1.09 (1.02 to 1.15) 0.010
Age 1.01 (0.95 to 1.07) 0.77
Diabetes in first-degree or second-degree relatives 0.84 (0.47 to 1.50) 0.55
GDM or macrosomia in a previous pregnancy 1.65 (0.93 to 3.37) 0.17
Total energy intake (MJ/day) 0.89 (0.80 to 1.06) 0.19
Dietary fibre (g/day) 1.02 (0.97 to 1.08) 0.37
Saturated fatty acids (E%)† 0.97 (0.85 to 1.10) 0.59
Total gestational weight gain 0.94 (0.89 to 0.99) 0.029
Women with Hb (8–12 weeks’ gestation‡) >120 g/l
Total Fe intake (the highest 20% vs the lowest 80%) 1.95 (1.005 to 3.78) 0.048 2.35 (1.13 to 4.92) 0.023
BMI 1.07 (1.00 to 1.14) 0.054
Age 1.01 (0.95 to 1.08) 0.76
Diabetes in first-degree or second-degree relatives 0.70 (0.38 to 1.31) 0.27
GDM or macrosomia in a previous pregnancy 1.60 (0.73 to 3.53) 0.24
Total energy intake (MJ/day) 0.83 (0.69 to 1.02) 0.071
Dietary fibre (g/day) 1.05 (0.99 to 1.11) 0.10
Saturated fatty acids (E%)† 0.99 (0.86 to 1.15) 0.92
Total gestational weight gain 0.93 (0.87 to 0.99) 0.017
*Adjusted for other variables in the model (total Fe intake, BMI, age, diabetes in first-degree or second-degree relatives, GDM or macrosomia
in a previous pregnancy, total energy intake, dietary fibre, saturated fatty acids and total gestational weight gain).
†Percentage of total energy intake.
‡16–18 weeks’ gestation for those with missing values at 8–12 weeks’ gestation (n=28).
BMI, body mass index; GDM, gestational diabetes mellitus; Hb, haemoglobin.
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has been conducted to investigate the association
between iron supplementation and GDM.24 This study
did not observe any association. However, it can be
argued that the intake of supplemental iron was quite
low in this study because of only about 50% compliance
to a daily supplement of 60 mg of elemental iron.
Iron is a highly reactive component with a possibility to
participate in harmful reactions.31 The human body can
excrete iron with very limited mechanisms and thus iron
intake is highly regulated according to body iron needs.32
Iron could interfere with glucose metabolism in several
ways. For example, following mechanisms have been pro-
posed: Iron decreases insulin extraction and metabolism in
the liver, which leads to peripheral hyperinsulinaemia.33
Iron overload results in oxidative stress in pancreatic β-cells,
which leads to destruction of the pancreatic islets and thus
decreases insulin secretion.34 The exact mechanisms,
which link iron to diabetes are still unsolved. However, the
association can be argued to be biologically plausible.
Accumulating body of evidence supports the hypoth-
esis of excess iron as a risk factor for glucose metabolism
disorders such as gestational diabetes. Iron deﬁciency
anaemia has been shown to reduce the incidence of
GDM.19 Respectively high haemoglobin level (>130 g/l)
in early pregnancy has been demonstrated to be an
independent risk factor for GDM.18 It seems that iron
can affect glucose metabolism even with no overt iron
overload. Women diagnosed with GDM have been
observed to have increased iron stores compared to
women without GDM.15 17 However, many of these
studies have been cross-sectional and it has been criti-
cised that higher serum ferritin levels could in fact
reﬂect inﬂammation in the body and could be rather a
result than a cause for diabetes.16
In summary it seems that high iron intake might be a
factor, which increases the risk of GDM especially in
women with already good iron stores. Use of iron supple-
ments during pregnancy is common even in women with
good haemoglobin levels. Our results suggest that routine
use of iron supplements should be reconsidered in non-
anaemic women with risk factors for GDM. To conﬁrm the
hypothesis there is need for a large prospective study—
ideally a randomised controlled trial—with reliable and
comprehensive information on iron intake from food and
supplements during pregnancy accompanied with serum
measurements to determine the level of body iron stores.
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